NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
HeartBeam (BEAT) Q3 2025 Conference Call and Company Overview FAQ
TL;DR
HeartBeam's upcoming earnings call provides investors early insight into regulatory progress and commercial milestones for its groundbreaking 3D ECG technology.
HeartBeam's portable device collects ECG signals from three directions and synthesizes them into a 12-lead ECG for remote cardiac monitoring.
HeartBeam's technology enables cardiac monitoring outside medical facilities, improving early detection and making heart care more accessible worldwide.
HeartBeam created the first cable-free device that captures 3D ECG signals, transforming how cardiac conditions are detected and monitored remotely.
Found this article helpful?
Share it with your network and spread the knowledge!
HeartBeam (NASDAQ: BEAT) will hold a conference call on Thursday, November 13, 2025, at 4:30 p.m. ET to discuss its third quarter 2025 results and provide updates on regulatory progress, commercial-readiness activities, and upcoming milestones.
The conference call is scheduled for Thursday, November 13, 2025, at 4:30 p.m. Eastern Time.
HeartBeam is creating the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing the signals into a 12-lead ECG, designed for portable use wherever the patient is located.
HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-Lead ECG synthesis software is currently under FDA review.
The technology enables physicians to identify cardiac health trends and acute conditions outside medical facilities, allowing patients to receive appropriate care guidance without needing to visit a healthcare facility.
The call will discuss third quarter 2025 results and provide updates on regulatory progress, commercial-readiness activities, and upcoming company milestones.
Investors can view the full press release at https://ibn.fm/5mXsb and access the latest news and updates in the company's newsroom at https://ibn.fm/BEAT.
The Company holds over 20 issued patents related to technology enablement for its 3D ECG platform.
The third quarter results cover the period ended September 30, 2025.
Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially, and investors should review the Risk Factors sections in the Company's SEC filings rather than relying solely on these statements for investment decisions.
Curated from NewMediaWire
